Navigation Links
S1 Biopharma Expands Focus to Include Male Sexual Health
Date:5/13/2012

JERSEY CITY, N.J., May 14, 2012 /PRNewswire/ -- S1 Biopharma, an early-stage biopharmaceutical company developing therapeutic solutions for Hypoactive Sexual Desire Disorder (HSDD) and related sexual dysfunctions, today announced its foray into male sexual health with S1P-205, the first and only drug in development for male HSDD.

The expansion into male sexual health represents S1 Biopharma's intent to take a comprehensive and holistic approach to treating HSDD, a clinical condition marked by persistent lack of desire, personal distress, and interpersonal difficulty.

"In the case of couples with one or both partners experiencing HSDD, there is a benefit to treating both genders together rather than treating one partner alone," said Nicolas G. Sitchon, CEO of S1 Biopharma. "S1P-205 and Lorexys—our drug for female HSDD—are perfect for this dual treatment approach."

With the development of S1P-205, S1 Biopharma is taking steps to address desire disparity between partners and dispelling the myth than men don't have problems with desire.

Targeting Desire Dysfunction
Desire dysfunction in males remains underserved by the biopharma community, despite the fact that PDE-5 inhibitor therapies like Viagra have a 43% non-response rate[1] —a rate suggesting that psychogenic factors deserve more attention than they're currently receiving.

Diverse research exists to support this view of desire dysfunction in males. A study of over a hundred female nurses in a relationship with a male partner found that 29.5% reported having more desire than their male partner.[2] 

An earlier study of a representative sample of non-geriatric U.S. adults found that 10.2% of men had "trouble maintaining/achieving an erection", while 15% of the men in the study  experienced a problematic "lack of interest in sex."[3] Put differently, the incidence of desire dysfunction in this sample of men was nearly one and a half times the incidence of erectile dysfunction (ED).

"Lack of desire—rather than some cardiovascular or physiological pathology—is a medical condition that can play a significant role in male sexual disorders," said Robert E. Pyke, Chief Medical Officer of S1 Biopharma. "PDE-5 inhibitor therapies are only half the story, and we hope to address the other half with S1P-205, helping men and their partners to have more fulfilling relationships."

About S1 Biopharma, Inc.
S1 Biopharma (formerly S1 Pharmaceuticals) is an early-stage biopharmaceutical company developing therapeutic solutions for Hypoactive Sexual Desire Disorder (HSDD) and related sexual dysfunctions.  S1 Biopharma's lead product, Lorexys, is the only non-hormonal therapy for HSDD in women. The company is also developing S1P-205 as the first and only therapy for HSDD in men. For additional information, visit www.s1biopharma.com.

[1] Sildenafil U.S. Labeling, 2012

[2] Sand M and Fisher WA, Rethinking Desire: Prevalence and Correlates of Desire Discordance in the Nurses Sexuality Study, 2007

[3] Laumann EO and Michael RT, Sex, Love, and Health in America, Chicago, 2000

Contact:
press@s1biopharma.com


'/>"/>
SOURCE S1 Biopharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
2. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
4. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
5. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
6. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
7. Equity Research on Most Popular Searches: Atmel, USG, Applied Materials, Sprint Nextel, Galena Biopharma, and Key Energy Services
8. PAREXEL Global Survey Results Identify Top Concerns of Biopharma Industry in Achieving Commercial Success
9. Pharmspective Announces the Release of ClearView™ - a New Health Care Reform Knowledge Management Web Application for the Biopharma Industry
10. PDL BioPharma Announces Conversion Rate Adjustments for Its Convertible Notes
11. Medtrack One View - A New More Powerful Biopharmaceutical Intelligence Tool Is Now Available
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ... on the development of oral drug delivery systems, announced today ... conference, presented by Joseph Gunnar & Co. LLC, ... York . Nadav Kidron , CEO of Oramed, ... Presentation Details:   PIONEERS 2016, presented by ...
(Date:4/27/2016)... Mass., April 27, 2016  Hologic, Inc. (Nasdaq: ... financial results for the fiscal second quarter ended ... (EPS) of $0.24 increased 41.2%, and non-GAAP diluted ... million increased 5.8% on a reported basis, and ... "We posted another good quarter, highlighted by ...
(Date:4/27/2016)... 27, 2016 Transparency Market Research ... Market - Global Industry Analysis, Size, Share, Growth, Trends, ... the global skincare devices market was valued at US$ ... at a CAGR of 10.1% from 2015 to 2023 ... Browse the full Skincare Devices Market (Treatment Device - LED ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 2016 , ... In an article published April 16th on the ... and lip injections, which she underwent in order to feel more at home at ... Festival. The article explains that Ms. Mirmelli’s situation is not unique; many plastic surgeons ...
(Date:4/29/2016)... Newport Beach, Calif. (PRWEB) , ... April 29, 2016 , ... ... affect us. An effective way to confront and deal with these stressors is to ... taste bad to be good for you. Risa Groux, a certified Holistic Nutritionist and ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House announced ... loans, more information about their loan terms and accounts, and more protections for ... including federal and private loans, has reached $1.3 trillion, with 43 million Americans ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a comprehensive spine physician ... one of their physicians has been invited to be a featured speaker at the ... Review conference on April 30, 2016. , Dr. R. Scott McPherson, a physical ...
(Date:4/29/2016)... ON (PRWEB) , ... April 29, 2016 , ... ... and the Canadian Celiac Association (CCA), is pleased to announce the launch of ... gluten-free products, nutritional articles, recipes, and more. The purpose of the GFCP ...
Breaking Medicine News(10 mins):